Supplementary Figure 1.docx (74.08 kB)
Download file

Supplementary Figure 1: Diagnostic and economic value of biomarker testing for targetable mutations in NSCLC: a literature review

Download (74.08 kB)
figure
posted on 06.12.2021, 10:05 by Ying Zheng, Helene Vioix, Frank X Liu, Barinder Singh, Sakshi Sharma, Deepti Sharda
Supplementary Figure 1: Methodology for the review process

Abstract

To assess the diagnostic and economic value of next-generation sequencing (NGS) vs single-gene testing, and liquid biopsy (LBx) vs tissue biopsy (TBx) in NSCLC biomarker testing through literature review. Embase® and MEDLINE® were searched to identify relevant studies (N=43) from 2015 to 2020 in adults with advanced NSCLC. For NGS vs single-gene testing, concordance was 70–99%, sensitivity was 86–100%. For LBx vs TBx, specificity was 43–100%, sensitivity was ≥60%. Turnaround times were longer for NGS vs single-gene testing (but not vs sequential testing) and faster for LBx vs TBx. NGS was cost-effective, and LBx reduced US per-patient costs. NGS vs single-gene testing and LBx vs TBx were concordant. NGS and LBx may be cost-effective for initial screening.

Funding

EMD Serono, Inc, a business of Merck Healthcare KGaA, Darmstadt, Germany

History